Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 58Lung Neoplasms 13Colorectal Neoplasms 11Neoplasms 8Mesothelioma, Malignant 7Mesothelioma 7Meningeal Carcinomatosis 7Neoplasm Metastasis 6Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Stomach Neoplasms 3Pancreatic Neoplasms 3Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3Advanced Solid Tumors 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms by Site 2NSCLC 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma 2Advanced Solid Tumor 2Urologic Neoplasms 1Solitary Fibrous Tumor, Pleural 1Rectal Neoplasms 1

Interventions

eltrombopag 1durvalumab 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Cytarabine 1Cisplatin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pathologic Complete Response × Pemetrexed × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡